Product Overview & Details for UCSF 41st Annual Advances in Heart Disease 2024
Include: 5 videos, size: 7.91 GB
Target Audience: cardiovascular specialists, practicing cardiologists, internists, family physicians, cardiovascular and critical care physician assistants
Information:
Our 41st annual course will again strive to present topics that highlight new evidence-based medicine findings reported within the last one to two years that impact clinical practice. These will range across a variety of weight loss drugs and heart health, heart failure, contemporary management of arrhythmias, critical care cardiology, mechanical circulatory support, erectile dysfunction and heart health, and pulmonary hypertension.
Our faculty will include a distinguished group of visiting academicians from North America together with outstanding teachers and clinicians from the University of California, San Francisco.
All sessions will be recorded and made available to participants for online viewing 30 days post course.
TARGET AUDIENCE
This course is intended for cardiovascular specialists, practicing cardiologists, internists, family physicians, cardiovascular and critical care nurses, and physician assistants.
Objectives
- Providing the Best Management of Coronary Heart Disease, Hypertension, Lipid Disorders, Diabetes, Systolic and Diastolic Heart Failure, Atrial Fibrillation and Flutter, STEMI and Non-STEMI, Thromboembolic Disease;
- Refining Considerations for Atrial Fibrillation, Atrial Flutter, and Ventricular Tachycardia Ablation;
- Applying the Best Considerations of Percutaneous Interventions for Coronary Heart Disease;
- Improving the Use of Anti-Platelet and Anti-Coagulation Therapy for Cardiovascular Diseases;
- Recognizing Risk Stratification of Cardiovascular Disease;
- Optimizing the Management of Peripheral Artery Disease;
- Recognizing that Pathophysiology of Diseases and Treatment Options Differ among Racial and Ethnic Groups;
- Optimizing the Management of COVID-19 and its Cardiovascular Complications.
Topics:
December 6 AM Session.mp4
December 6 PM Session.mp4
December 7 AM Session.mp4
December 7 PM Session.mp4
December 8 AM Session.mp4
Detail:
| Friday, December 6, 2024 | ||
| 7:00 AM | Registration and Continental Breakfast | |
| 8:00 | Welcome and Symposium Overview | Peter Ganz, MD |
| Session: Frontiers in Interventional Cardiology | Chair: Lucas Zier, MD, MSÂ | |
| 8:05 | Myocardial Infarction Without Obstructive Coronary Disease. What to Do? | Krishan Soni, MD, MBA |
| 8:45 | Complete Revascularization vs Culprit Only Revascularization: Understanding Each Strategy and When to Perform Each Approach | Ada Ip, MD |
| 9:25 | Orbita vs Orbita 2: Update on PCI for Stable CAD. | Lucas Zier, MD, MS |
| 10:05 | Coffee Break | |
| 10:20 | 2024 Updates on the Management of Valve Disease | Sammy Elmariah , MD, MPH |
| 11:00 | Surgical Management of Type A Aortic Dissection | Ramin Beygui, MD |
| 11:40 | Circulatory Support in Cardiogenic Shock: New Data and a New Era? | Connor O’Brien, MD |
| 12:20 PM | Lunch (on Your Own) | |
| Session: Managing Heart Failure | Chair: Jonathan Davis, MD, MPH | |
| 1:40 PM | New Drugs and Devices Coming Down Pipeline for Heart Failure | Liviu Klein, MD, MS |
| 2:15 | Genetic Testing for Heart Failure, Who Should Be Tested and What are We Looking For? | Julianne Wojciak, LGCG, MS |
| 2:50 | HFrEF Management | Jonathan Davis, MD, MPH |
| 3:25 | Coffee Break | |
| 3:40 | HFpEF Management | Jacqueline DesJardin, MD |
| 4:15 | Approach to and Management of Hypertrophic Cardiomyopathy | Theodore Abraham, MD |
| 4:50 | Approach to and Management of Cardiac Amyloid | Mandar Aras, MD, PhD |
| 5:25 PM | Adjourn | |
| Saturday, December 7, 2024 | ||
| 7:30 AM | Continental Breakfast | |
| 8:00 | Announcements | Peter Ganz, MD |
| Session: Advances and Controversies in Electrophysiology | Chair: Nora Goldschlager, MD | |
| 8:05 | Use and Misuse of Antiarrhythmic Drugs in 2025 | Gregory Marcus, MD, MAS |
| 8:45 | Extravascular Pacemakers and ICDs: Where Have All the Leads Gone? | Adam Oesterle, MD |
| 9:25 | Conduction System Pacing: Benefits, Outcomes and Risks | Joshua Moss, MD |
| 10:05 | Coffee Break | |
| 10:20 | Arrhythmogenic  Cardiomyopathy | Melvin Scheinman, MD |
| 11:00 | What to Do with Incidentally Detected Atrial Fibrillation | Cara Pellegrini, MD |
| 11:40 | PVCs and non-Sustained VT. When to Worry. | Edward Gerstenfeld, MD, MS |
| 12:20 | Lunch (on your own) | |
| 1:40 PM | Achieving a Successful Ablation. Achieving a Successful Ablation. Patient Selection and Outcomes. | Thomas Dewland, MD |
| Session: Cardiovascular Risk Reduction and Prevention | Chair: Peter Ganz, MD | |
| 2:20 | Elliot Rapaport Keynote Lecture: How Failed Diabetes Drugs Led to a Revolution in Diabetes and Heart Failure Care. Convincing the FDA to Mandate Cardiovascular Outcome Trials for Diabetes Drug Approval | Steven Nissen, MD |
| 3:05 | New Prediction Tools from the AHA for Risk Assessment of Cardiovascular Disease | Peter Ganz, MD |
| 3:45 | Coffee Break | |
| 4:00 | Cardiovascular Disease in Type 1 Diabetes | Robert Eckel, MD |
| 4:40 | Pulmonary Hypertension, Contemporary Management and When to Refer | Marc Simon, MD, MS |
| 5:20 PM | Adjourn | |
| Sunday, December 8, 2024 | ||
| 7:30 AM | Continental Breakfast | |
| 8:00 | Announcements | Peter Ganz, MD |
| Session: Understanding and Managing Cardiovascular Risk | Chair: Peter Ganz, MD | |
| 8:05 | Sex diversity in heart-liver-metabolic axis risks and outcomes | Susan Cheng, MD, MMSc, MPH |
| 8:45 | PDE-5 inhibitors for Erectile Dysfunction: Do They Have Cardiovascular Protective Properties | Robert Kloner, MD, PhD |
| 9:25 | The Interplay of Cardiovascular and Kidney Disease | Julio Lamprea Montealegre, MD, PhD, MPH |
| 10:05 | Insights from Basic Science to Advance Understanding of Heart Failure | Arun Padmanabhan, MD, PhD |
| 10:25 | Weight Loss Drugs and Heart Health | Martha Gulati, MD, MS |
| 11:05 | Management of Stroke – Updates | Lauren Patrick, MD |
| 11:45 | Adjourn | |
